A proposed management pathway for community-acquired Gram-negative sepsis in Chinese older adults.

Authors

Liling Jing, Weiwei Zhang, Yunlong Liu

Published in

Journal of infection in developing countries. Volume 20. Issue 8. Pages 1161-1170. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

Sepsis epidemiology varies regionally. We aimed to characterise community-acquired sepsis in Chinese older adults and develop an evidence-based, cost-effective empirical therapeutic pathway tailored to local antimicrobial-resistance patterns.
This single-centre, retrospective observational cohort study conducted at a tertiary hospital in Shanghai, China, enrolled 122 consecutive older adults (age ≥ 65 years) meeting Sepsis-3 criteria between June 2021 and May 2023. Microbiological data, antimicrobial-susceptibility profiles, clinical characteristics, and 28-day all-cause mortality were analysed. Multivariate logistic regression was used to identify independent risk factors for mortality.
Gram-negative bacteria predominated (54.9%) and showed high susceptibility to cefoperazone-sulbactam (85.0%). The 28-day mortality rate was 37.7%. Multivariate analysis identified increasing age (adjusted odds ratio [aOR] = 1.10 per year), need for intensive care unit admission (aOR = 6.65), mechanical ventilation (aOR = 5.78), and dialysis (aOR = 3.62) as independent predictors of mortality. Notably, adequate empirical antimicrobial therapy was not an independent protective factor in the adjusted model. A cost-effective clinical pathway with cefoperazone-sulbactam as the first-line empirical therapy and escalation based on clinical response was developed for use in resource-limited settings.
The findings underscore the dominance of Gram-negative pathogens and the critical influence of host factors on survival among older adults with sepsis in China. They also provide a carbapenem-sparing, pragmatic, and sustainable management pathway for initial sepsis treatment in resource-limited settings, which can be replicated for antimicrobial stewardship in other regions with similar epidemiological profiles. The clinical effectiveness of this hypothesis-generating pathway requires validation in prospective, multicentre studies..

PMID:
42715272
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.